HFPEF 评分在射血分数保留心衰全球临床试验中的应用：TOPCAT 试验。
Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.
机构信息
Brigham and Women's Hospital, Boston, MA, USA.
Akershus University Hospital and University of Oslo, Oslo, Norway.
出版信息
Eur J Heart Fail. 2019 Oct;21(10):1288-1291. doi: 10.1002/ejhf.1542. Epub 2019 Jul 22.
Abstract
TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial); ClinicalTrials.gov Identifier:
摘要
TOPCAT（醛固酮拮抗剂治疗保留射血分数心力衰竭试验）；ClinicalTrials.gov 标识符：
相似文献
1
Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.HFPEF 评分在射血分数保留心衰全球临床试验中的应用：TOPCAT 试验。
Eur J Heart Fail. 2019 Oct;21(10):1288-1291. doi: 10.1002/ejhf.1542. Epub 2019 Jul 22.
2
Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.随机临床试验参与者的计算表型映射，以评估其真实世界代表性和个性化推断
Circ Cardiovasc Qual Outcomes. 2025 May;18(5):e011306. doi: 10.1161/CIRCOUTCOMES.124.011306. Epub 2025 Apr 22.
3
Myocardial contraction fraction predicts outcomes in patients enrolled in the TOPCAT trial.心肌收缩分数可预测参加TOPCAT试验患者的预后。
Int J Cardiol. 2025 Apr 1;424:133038. doi: 10.1016/j.ijcard.2025.133038. Epub 2025 Feb 4.
4
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.TOPCAT 试验中醛固酮拮抗剂治疗心脏收缩功能保留心力衰竭患者及结局的地域差异。
Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.
5
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.螺内酯与利钠肽在射血分数保留的心力衰竭患者中的相互作用：来自 TOPCAT 试验。
JACC Heart Fail. 2017 Apr;5(4):241-252. doi: 10.1016/j.jchf.2016.11.015.
6
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.螺内酯对射血分数保留的心力衰竭患者心脏结构和功能的影响：三项随机试验的汇总分析
Eur J Heart Fail. 2023 Jan;25(1):108-113. doi: 10.1002/ejhf.2726. Epub 2022 Nov 9.
7
A review regarding the article 'Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a network meta-analysis of 32 randomized trials'.关于文章《射血分数降低的心力衰竭中使用盐皮质激素受体拮抗剂：32 项随机试验的网络荟萃分析》的综述。
Curr Probl Cardiol. 2024 Aug;49(8):102644. doi: 10.1016/j.cpcardiol.2024.102644. Epub 2024 May 13.
8
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.用于射血分数保留的慢性心力衰竭的β受体阻滞剂和肾素-血管紧张素-醛固酮系统抑制剂。
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2.
9
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.心力衰竭伴射血分数保留与药物超适应证联用的相关性研究。
Circ Heart Fail. 2021 Nov;14(11):e008293. doi: 10.1161/CIRCHEARTFAILURE.120.008293. Epub 2021 Oct 22.
10
Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?螺内酯用于射血分数保留的心力衰竭的管理：TOPCAT研究之后何去何从？
Curr Atheroscler Rep. 2015 Nov;17(11):64. doi: 10.1007/s11883-015-0541-6.
引用本文的文献
1
The role of echocardiography in the diagnosis of heart failure with preserved ejection fraction.超声心动图在射血分数保留的心力衰竭诊断中的作用。
Heart Fail Rev. 2025 May 12. doi: 10.1007/s10741-025-10516-z.
2
New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.射血分数保留的心力衰竭的新机遇：从 bench 到 bedside……再回归
Biomedicines. 2022 Dec 27;11(1):70. doi: 10.3390/biomedicines11010070.
3
Value of the HFA-PEFF and H FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.心脏淀粉样变所致射血分数保留心力衰竭患者的 HFA-PEFF 和 H FPEF 评分的价值。
Eur J Heart Fail. 2022 Dec;24(12):2374-2386. doi: 10.1002/ejhf.2616. Epub 2022 Aug 15.
4
Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations.射血分数保留的心力衰竭更新：临床试验和新治疗考虑因素的综述。
Cardiol J. 2022;29(4):670-679. doi: 10.5603/CJ.a2022.0051. Epub 2022 Jun 28.
5
Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction.多模态心血管成像在射血分数保留的心力衰竭诊断中的进展
Front Cardiovasc Med. 2022 Mar 9;9:758975. doi: 10.3389/fcvm.2022.758975. eCollection 2022.
6
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.人类和小鼠射血分数保留型心力衰竭：在小鼠模型中接受临床复杂性。
Eur Heart J. 2021 Nov 14;42(43):4420-4430. doi: 10.1093/eurheartj/ehab389.
7
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems.射血分数保留的心力衰竭评分系统的诊断和预后意义
ESC Heart Fail. 2021 Jun;8(3):2089-2102. doi: 10.1002/ehf2.13288. Epub 2021 Mar 11.
8
Impact of Updated 2016 ASE/EACVI VIS-À-VIS 2009 ASE Recommendation on the Prevalence of Diastolic Dysfunction and LV Filling Pressures in Patients with Preserved Ejection Fraction.2016年美国超声心动图学会（ASE）/欧洲心血管影像学会（EACVI）更新版相对于2009年ASE推荐对射血分数保留患者舒张功能障碍患病率和左心室充盈压的影响
J Cardiovasc Imaging. 2021 Jan;29(1):31-43. doi: 10.4250/jcvi.2020.0117.
9
Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations.射血分数保留的心力衰竭（HFpEF）患者的诊断与管理：当前观点与建议
Ther Clin Risk Manag. 2020 Aug 21;16:769-785. doi: 10.2147/TCRM.S207117. eCollection 2020.
10
Evaluation and management of heart failure with preserved ejection fraction.射血分数保留的心力衰竭的评估和管理。
Nat Rev Cardiol. 2020 Sep;17(9):559-573. doi: 10.1038/s41569-020-0363-2. Epub 2020 Mar 30.
本文引用的文献
1
External Validation of the HF-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction.心力衰竭射血分数保留患者诊断中HF-PEF模型的外部验证
Circulation. 2019 May 14;139(20):2377-2379. doi: 10.1161/CIRCULATIONAHA.118.038594.
2
Generalizability and Implications of the HFPEF Score in a Cohort of Patients With Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭患者队列中HFPEF评分的可推广性及意义
Circulation. 2019 Apr 9;139(15):1851-1853. doi: 10.1161/CIRCULATIONAHA.118.039051.
3
Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.入组国家收入水平与患者资料、方案完成情况及试验终点之间的关系。
Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.
4
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.利钠肽与射血分数保留的心力衰竭患者心血管预后的相关性：TOPCAT 随机临床试验的二次分析。
JAMA Cardiol. 2018 Oct 1;3(10):1000-1005. doi: 10.1001/jamacardio.2018.2568.
5
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.一种简单、基于证据的方法，有助于指导射血分数保留的心力衰竭的诊断。
Circulation. 2018 Aug 28;138(9):861-870. doi: 10.1161/CIRCULATIONAHA.118.034646.
6
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.TOPCAT 试验中醛固酮拮抗剂治疗心脏收缩功能保留心力衰竭患者及结局的地域差异。
Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.
7
Spironolactone for heart failure with preserved ejection fraction.螺内酯治疗射血分数保留的心力衰竭。
N Engl J Med. 2014 Apr 10;370(15):1383-92. doi: 10.1056/NEJMoa1313731.
8
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.射血分数保留心力衰竭中心脏结构和功能：醛固酮拮抗剂治疗保留心脏功能心力衰竭的超声心动图研究的基线发现。
Circ Heart Fail. 2014 Jan;7(1):104-15. doi: 10.1161/CIRCHEARTFAILURE.113.000887. Epub 2013 Nov 18.
Zotero 插件